NEW YORK (360Dx) – With Roche's entry into the digital hematology space, the firm is looking to crack open a $2.8 billion market opportunity that doesn't even include point-of-care, or "specialty marker," hematology testing.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.